Literature DB >> 22405590

Pharmacotherapy challenges in patients with first-episode psychosis.

Amal Abdel-Baki1, Clairélaine Ouellet-Plamondon, Ashok Malla.   

Abstract

The first episode of a psychotic disorder typically occurs in late adolescence or young adulthood, a critical time of development with respect to personality, social role, education, and vocation. The first few years of psychosis appear to be a critical period during which intervention needs to be initiated before the consequences of psychosis become more severe. Early intervention is therefore crucial in maximizing outcomes. Although response rates to antipsychotic medication in first-episode psychosis (FEP) are good, there is a relatively high risk of relapse. The greatest challenges that physicians face in treating FEP and preventing relapse are engaging patients in treatment and preventing non-adherence to therapy. Overall rates of non-adherence to antipsychotic medications for FEP patients are estimated to be at or higher than 50% within the first year of treatment, suggesting that malleable factors linked to non-adherence need to be targeted in interventions provided. Factors influencing adherence can be categorized into four groups: (1) environment-related, (2) patient-related, (3) medication-related, and (4) illness-related. This paper will review the factors associated with adherence and discuss solutions to optimize engagement, adherence to medication, and treatment in order to prevent relapse. Factors like social and family support, therapeutic alliance, attitudes and beliefs toward illness and medication, insight, substance use disorders, medication efficacy, tolerability, and accessibility will be discussed. Solutions, such as early psychosis specialized services integrating psychosocial therapies and careful selection of appropriate antipsychotic medication, will be proposed. Copyright Â
© 2012. Published by Elsevier B.V.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22405590     DOI: 10.1016/j.jad.2012.02.029

Source DB:  PubMed          Journal:  J Affect Disord        ISSN: 0165-0327            Impact factor:   4.839


  12 in total

1.  Medication adherence in first episode psychosis: the role of pre-onset subthreshold symptoms.

Authors:  J-G Daneault; A Maraj; M Lepage; A Malla; N Schmitz; S N Iyer; R Joober; J L Shah
Journal:  Acta Psychiatr Scand       Date:  2019-04       Impact factor: 6.392

Review 2.  Altering the course of schizophrenia: progress and perspectives.

Authors:  Mark J Millan; Annie Andrieux; George Bartzokis; Kristin Cadenhead; Paola Dazzan; Paolo Fusar-Poli; Jürgen Gallinat; Jay Giedd; Dennis R Grayson; Markus Heinrichs; René Kahn; Marie-Odile Krebs; Marion Leboyer; David Lewis; Oscar Marin; Philippe Marin; Andreas Meyer-Lindenberg; Patrick McGorry; Philip McGuire; Michael J Owen; Paul Patterson; Akira Sawa; Michael Spedding; Peter Uhlhaas; Flora Vaccarino; Claes Wahlestedt; Daniel Weinberger
Journal:  Nat Rev Drug Discov       Date:  2016-03-04       Impact factor: 84.694

3.  Treatment of first-episode non-affective psychosis: a randomized comparison of aripiprazole, quetiapine and ziprasidone over 1 year.

Authors:  Benedicto Crespo-Facorro; Victor Ortiz-Garcia de la Foz; Ignacio Mata; Rosa Ayesa-Arriola; Paula Suarez-Pinilla; Elsa M Valdizan; Obdulia Martinez-Garcia; Rocío Pérez-Iglesias
Journal:  Psychopharmacology (Berl)       Date:  2014-01       Impact factor: 4.530

4.  Three-Year Naturalistic Study On Early Use Of Long-Acting Injectable Antipsychotics In First Episode Psychosis.

Authors:  Sofia Medrano; Amal Abdel-Baki; Emmanuel Stip; Stéphane Potvin
Journal:  Psychopharmacol Bull       Date:  2018-06-20

5.  Factors Associated with Medication Adherence Among Patients with Severe Mental Disorders in China: A Propensity Score Matching Study.

Authors:  Lei Dou; Lili Hu; Nan Zhang; Henry Cutler; Yan Wang; Shunping Li
Journal:  Patient Prefer Adherence       Date:  2020-07-31       Impact factor: 2.711

6.  Modeling determinants of medication attitudes and poor adherence in early nonaffective psychosis: implications for intervention.

Authors:  Richard J Drake; Merete Nordentoft; Gillian Haddock; Celso Arango; W Wolfgang Fleischhacker; Birte Glenthøj; Marion Leboyer; Stefan Leucht; Markus Leweke; Phillip McGuire; Andreas Meyer-Lindenberg; Dan Rujescu; Iris E Sommer; René S Kahn; Shon W Lewis
Journal:  Schizophr Bull       Date:  2015-03-05       Impact factor: 9.306

Review 7.  Current Data on and Clinical Insights into the Treatment of First Episode Nonaffective Psychosis: A Comprehensive Review.

Authors:  Benedicto Crespo-Facorro; Jose Maria Pelayo-Teran; Jacqueline Mayoral-van Son
Journal:  Neurol Ther       Date:  2016-08-23

8.  Adherence, healthcare resource utilization and Medicaid spending associated with once-monthly paliperidone palmitate versus oral atypical antipsychotic treatment among adults recently diagnosed with schizophrenia.

Authors:  Dominic Pilon; Erik Muser; Patrick Lefebvre; Rhiannon Kamstra; Bruno Emond; Kruti Joshi
Journal:  BMC Psychiatry       Date:  2017-06-02       Impact factor: 3.630

9.  [Long-acting antipsychotics: The QAAPAPLE algorithm review].

Authors:  Emmanuel Stip; Amal Abdel-Baki; Marc-André Roy; David Bloom; Sylvain Grignon
Journal:  Can J Psychiatry       Date:  2019-05-14       Impact factor: 4.356

10.  Antipsychotic Prescribing Patterns in First-episode Schizophrenia: A Five-year Comparison.

Authors:  Daeyoung Roh; Jhin-Goo Chang; Sol Yoon; Chan-Hyung Kim
Journal:  Clin Psychopharmacol Neurosci       Date:  2015-12-31       Impact factor: 2.582

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.